

# American Cancer Society Guideline for the Early Detect

Ca-A Cancer Journal for Clinicians

60, 70-98

DOI: [10.3322/caac.20066](https://doi.org/10.3322/caac.20066)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Screening for prostate cancer. , 2006, , CD004720.		74
2	Prostate Cancer Screening 2010: Updated Recommendations From the American Cancer Society. Journal of the National Medical Association, 2010, 102, 423-429.	0.6	32
5	Patient-Centered Discussions About Prostate Cancer Screening: A Real-World Approach. Annals of Internal Medicine, 2010, 153, 661.	2.0	18
6	What Happens After an Elevated PSA Test: The Experience of 13,591 Veterans. Journal of General Internal Medicine, 2010, 25, 1205-1210.	1.3	17
7	Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening. Ca-A Cancer Journal for Clinicians, 2010, 60, 99-119.	157.7	405
8	Introducing the 2010 American Cancer Society Prostate Cancer Screening Guideline. Ca-A Cancer Journal for Clinicians, 2010, 60, 68-69.	157.7	17
9	Osteopontin Plasma Level Does Not Detect Prostate Cancer in Patients Referred for Diagnostic Prostate Biopsy. International Journal of Biological Markers, 2010, 25, 200-206.	0.7	6
10	Management of the asymptomatic BRCA mutation carrier. The Application of Clinical Genetics, 2010, 3, 121.	1.4	6
11	Guidelines for Testosterone Therapy for Men: How to Avoid a Mad (T)ea Party by Getting Personal. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2614-2617.	1.8	17
12	Incidental fleurodeoxyglucose uptake in the prostate. British Journal of Radiology, 2010, 83, 902-903.	1.0	2
13	Molecular genetics of prostate cancer: new prospects for old challenges. Genes and Development, 2010, 24, 1967-2000.	2.7	811
14	Automatic decision using dirty databases: Application to prostate cancer diagnosis. , 2010, 2010, 1162-5.		1
15	Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2010, 341, c4543-c4543.	2.4	257
16	The Future of Health Journalism. Public Health Forum, 2010, 18, 19-20.	0.1	5
19	Prospective Evaluation of Operating Characteristics of Prostate Cancer Detection Biomarkers. Journal of Urology, 2011, 185, 104-110.	0.2	27
20	Use and Assessment of PSA in Prostate Cancer. Medical Clinics of North America, 2011, 95, 191-200.	1.1	34
21	Screening for Prostate Cancer. New England Journal of Medicine, 2011, 365, 2013-2019.	13.9	183
22	Zoledronic Acid Induces Autophagic Cell Death in Human Prostate Cancer Cells. Journal of Urology, 2011, 185, 1490-1496.	0.2	46

#	ARTICLE	IF	CITATIONS
23	The uncertain relationship between obesity and prostate cancer: An Italian biopsy cohort analysis. <i>European Journal of Surgical Oncology</i> , 2011, 37, 1025-1029.	0.5	23
24	Cancer screening in older adults: What to do when we don't know. <i>Journal of Geriatric Oncology</i> , 2011, 2, 149-160.	0.5	7
25	The decision-making process in prostate cancer screening in primary care with a prostate-specific antigen: A systematic review. <i>Journal of Geriatric Oncology</i> , 2011, 2, 161-176.	0.5	7
26	The Prostate-Specific Antigen Screening Conundrum: Examining the Evidence. <i>Seminars in Oncology Nursing</i> , 2011, 27, 251-259.	0.7	6
27	Implications of Treatment on Body Image and Quality of Life. <i>Seminars in Oncology Nursing</i> , 2011, 27, 290-299.	0.7	15
28	Variable Prostate-specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Care Medical Center. <i>Urology</i> , 2011, 78, 244-248.	0.5	6
29	Magnetic resonance spectroscopy: A promising tool for the diagnostics of human prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 562-571.	0.8	8
30	Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. <i>Lancet Oncology</i> , The, 2011, 12, 891-899.	5.1	311
31	Shared decision making in the United States: policy and implementation activity on multiple fronts. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2011, 105, 305-312.	0.7	87
32	PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. <i>Asian Journal of Andrology</i> , 2011, 13, 219-224.	0.8	21
34	Primary care perspectives on Prostate cancer screening. <i>Nurse Practitioner</i> , 2011, 36, 39-44.	0.2	1
35	Prostate-specific antigen screening in elderly men. <i>Aging Health</i> , 2011, 7, 219-229.	0.3	0
36	Low-dose rate brachytherapy for men with localized prostate cancer. <i>The Cochrane Library</i> , 2011, , CD008871.	1.5	29
37	The hedgehog/Gli signaling paradigm in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 453-467.	1.2	36
38	Translating Medical Evidence to Promote Informed Health Care Decisions. <i>Health Services Research</i> , 2011, 46, 1200-1223.	1.0	11
39	External Validation of an Index to Predict Up to 9â€¢Year Mortality of Communityâ€¢dwelling Adults Aged 65 and Older. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1444-1451.	1.3	101
40	Perspective on prostate cancer screening. <i>International Journal of Clinical Practice</i> , 2011, 65, 31-34.	0.8	3
41	Understanding preventive behaviors among mid-Western African-American men: a pilot qualitative study of prostate screening. <i>Journal of Men's Health</i> , 2011, 8, 140-151.	0.1	22

#	ARTICLE	IF	CITATIONS
42	Cancer screening in the United States, 2011. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 8-30.	157.7	291
43	Promoting cancer screening within the patient centered medical home. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 397-408.	157.7	37
44	Autoantibodies as Biomarkers in Cancer. <i>Laboratory Medicine</i> , 2011, 42, 623-628.	0.8	27
45	Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 310-316.	0.8	17
46	Risk Prediction of Complex Diseases from Family History and Known Susceptibility Loci, with Applications for Cancer Screening. <i>American Journal of Human Genetics</i> , 2011, 88, 548-565.	2.6	80
47	Factors Influencing Men's Decisions Regarding Prostate Cancer Screening: A Qualitative Study. <i>Journal of Community Health</i> , 2011, 36, 839-844.	1.9	42
48	Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. <i>Journal of Nanoparticle Research</i> , 2011, 13, 4717-4729.	0.8	51
50	A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: A cluster RCT. <i>Patient Education and Counseling</i> , 2011, 84, e44-e51.	1.0	37
51	Incidental Focal 18F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria. <i>Nuclear Medicine and Molecular Imaging</i> , 2011, 45, 192-196.	0.6	23
52	Correlates of Colorectal Cancer Screening Adherence Among Men Who have been Screened for Prostate Cancer. <i>Journal of Cancer Education</i> , 2011, 26, 301-307.	0.6	9
53	Discussions About Prostate Cancer Screening Between U.S. Primary Care Physicians and Their Patients. <i>Journal of General Internal Medicine</i> , 2011, 26, 1098-1104.	1.3	19
54	Prostate Cancer Screening. <i>Current Oncology Reports</i> , 2011, 13, 57-62.	1.8	22
55	Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening. <i>BMC Cancer</i> , 2011, 11, 148.	1.1	15
56	Impact of health system challenges on prostate cancer control: health care experiences in Nigeria. <i>Infectious Agents and Cancer</i> , 2011, 6, S5.	1.2	15
57	Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. <i>Prostate</i> , 2011, 71, 1492-1498.	1.2	58
58	Kallikrein-related peptidase 4 gene ( <i>KLK4</i> ) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. <i>Prostate</i> , 2011, 71, 1780-1789.	1.2	28
59	Automatic computer aided detection of abnormalities in multi-parametric prostate MRI. <i>Proceedings of SPIE</i> , 2011, , .	0.8	28
60	Prostate-Cancer Screening "What the U.S. Preventive Services Task Force Left Out. <i>New England Journal of Medicine</i> , 2011, 365, 1949-1951.	13.9	68

#	ARTICLE	IF	CITATIONS
61	Use of radial basis functions in computer-aided diagnosis of prostate cancer. , 2011, 2011, 6422-5.		0
62	A fully automatic method to register the prostate gland on T2-weighted and EPI-DWI images. , 2011, 2011, 8029-32.		4
63	Reversals of Association for Pap, Colorectal, and Prostate Cancer Testing among Hispanic and Non-Hispanic Black Women and Men. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 876-889.	1.1	6
64	Grading the New US Preventive Services Task Force Prostate Cancer Screening Recommendation. JAMA - Journal of the American Medical Association, 2011, 306, 2715.	3.8	20
65	Imaging in Prostate Cancer Diagnosis: Present Role and Future Perspectives. Urologia Internationalis, 2011, 86, 373-382.	0.6	56
66	Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. Journal of Clinical Oncology, 2011, 29, 1736-1743.	0.8	100
67	One Man at a Time â€” Resolving the PSA Controversy. New England Journal of Medicine, 2011, 365, 1951-1953.	13.9	68
68	Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer and Prostatic Diseases, 2011, 14, 346-353.	2.0	29
69	Prostate's PTEN prognosis. Science-Business EXchange, 2011, 4, 241-241.	0.0	0
70	Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer and Prostatic Diseases, 2011, 14, 253-261.	2.0	29
71	Targeting the CB2 cannabinoid receptor in osteoporosis. Expert Review of Endocrinology and Metabolism, 2011, 6, 135-138.	1.2	31
72	H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples. Biomarker Insights, 2011, 6, BMI.S6794.	1.0	45
73	Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Canadian Urological Association Journal, 2012, 6, 188-193.	0.3	12
74	Presenting Treatment Options to Men with Clinically Localized Prostate Cancer: The Acceptability of Active Surveillance/Monitoring. Journal of the National Cancer Institute Monographs, 2012, 2012, 191-196.	0.9	18
75	Reconciling Primary Care and Specialist Perspectives on Prostate Cancer Screening. Annals of Family Medicine, 2012, 10, 568-571.	0.9	10
76	Limited PSA Testing in Indigent Men in South Texas: An Appropriate Care or Missing a Prevention Opportunity?. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1489-1496.	1.1	3
77	Current status of transrectal ultrasound techniques in prostate cancer. Current Opinion in Urology, 2012, 22, 297-302.	0.9	54
78	Image guidance in the focal treatment of prostate cancer. Current Opinion in Urology, 2012, 22, 328-335.	0.9	14

#	ARTICLE	IF	CITATIONS
79	Recommendations on Use of Prostate-Specific Antigen for Prostate Cancer Screening—Reply. JAMA - Journal of the American Medical Association, 2012, 307, 1372.	3.8	0
80	It Takes Two to Talk About Prostate Cancer. American Journal of Men's Health, 2012, 6, 472-484.	0.7	45
81	Prostate-Specific Antigen Screening for Prostate Cancer in Older Men in the United States of America. Gerontology, 2012, 58, 331-336.	1.4	2
82	PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer and Prostatic Diseases, 2012, 15, 189-194.	2.0	22
83	To be screened or not to be screened? Modeling the consequences of PSA screening for the individual. British Journal of Cancer, 2012, 107, 778-784.	2.9	26
84	The Use of the Finasteride-Adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican Referral Population: A Validation Study. Urologia Internationalis, 2012, 89, 9-16.	0.6	5
85	Measuring Informed Decision Making about Prostate Cancer Screening in Primary Care. Medical Decision Making, 2012, 32, 327-336.	1.2	28
86	Prostate cancer screening practices in the Republic of Ireland: The determinants of uptake. Journal of Health Services Research and Policy, 2012, 17, 206-211.	0.8	16
87	Are We Worrying About the Right Men and Are the Right Men Feeling Worried? Conscious But Not Unconscious Prostate Anxiety Predicts Screening Among Men From Three Ethnic Groups. American Journal of Men's Health, 2012, 6, 37-50.	0.7	10
88	Prognostic Indices for Older Adults. JAMA - Journal of the American Medical Association, 2012, 307, 182.	3.8	637
89	A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia. Radiology and Oncology, 2012, 46, 69-74.	0.6	27
90	Is Age a Risk Factor for Hypothyroidism in Pregnancy? An Analysis of 5223 Pregnant Women. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1945-1952.	1.8	37
91	Critical Appraisal Process. Southern Medical Journal, 2012, 105, 144-148.	0.3	5
92	Photoacoustic imaging of prostate cancer using cylinder diffuse radiation. , 2012, , .		4
93	The Influence of Stress, Depression, and Anxiety on PSA Screening Rates in a Nationally Representative Sample. Medical Care, 2012, 50, 1037-1044.	1.1	25
94	New Insights Into the Pathogenesis of Ovarian Carcinoma. Obstetrics and Gynecology, 2012, 120, 935-940.	1.2	27
96	Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 2012, 157, 120.	2.0	1,872
97	Primary Care Providers' Response to the US Preventive Services Task Force Draft Recommendations on Screening for Prostate Cancer. Archives of Internal Medicine, 2012, 172, 668.	4.3	25

#	ARTICLE	IF	CITATIONS
98	Prostate cancer screening among ethnically diverse first-degree relatives of prostate cancer cases.. Health Psychology, 2012, 31, 562-570.	1.3	9
99	A Search for Reliable Molecular Markers of Prognosis in Prostate Cancer. American Journal of Clinical Pathology, 2012, 137, 918-930.	0.4	35
100	Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Management Science, 2012, 15, 293-309.	1.5	22
101	Matched Cohort Analysis of Outcomes of Definitive Radiotherapy for Prostate Cancer in Human Immunodeficiency Virus-Positive Patients. International Journal of Radiation Oncology Biology Physics, 2012, 83, 16-21.	0.4	25
103	Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Annals of Oncology, 2012, 23, 1325-1334.	0.6	90
104	Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. Journal of Clinical Oncology, 2012, 30, 3734-3745.	0.8	263
105	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Science Translational Medicine, 2012, 4, 127rv3.	5.8	378
106	Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor. Biosensors, 2012, 2, 377-387.	2.3	25
107	Landmarks in prostate cancer screening. BJU International, 2012, 110, 3-7.	1.3	30
108	A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer. American Journal of Pathology, 2012, 181, 1585-1594.	1.9	41
109	Remaining life expectancy measurement and PSA screening of older men. Journal of Geriatric Oncology, 2012, 3, 196-204.	0.5	14
110	Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Medical Oncology, 2012, 29, 1964-1971.	1.2	15
111	Informed Decision Making About Prostate Cancer Testing in Predominantly Immigrant Black Men: A Randomized Controlled Trial. Annals of Behavioral Medicine, 2012, 44, 320-330.	1.7	48
112	Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trials. BMC Medical Informatics and Decision Making, 2012, 12, 130.	1.5	38
113	Pathobiological Implications of the Expression of EGFR, pAkt, NF- $\kappa$ B and MIC-1 in Prostate Cancer Stem Cells and Their Progenies. PLoS ONE, 2012, 7, e31919.	1.1	46
114	Recent Trends in Prostate Cancer Incidence by Age, Cancer Stage, and Grade, the United States, 2001-2007. Prostate Cancer, 2012, 2012, 1-8.	0.4	107
115	Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years of Age. Journal of Korean Medical Science, 2012, 27, 40.	1.1	7
116	The Prostate Cancer Screening Controversy: Addressing Bioethical Concerns at a Community Health Promotion Event for Men. Journal of Health Care for the Poor and Underserved, 2012, 23, 11-14.	0.4	4

#	ARTICLE	IF	CITATIONS
117	Review of guidelines on diagnosis and treatment of testosterone deficiency. , 2012, , 408-420.		7
118	Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate, 2012, 72, 129-146.	1.2	48
119	The Epigenetic promise for prostate cancer diagnosis. Prostate, 2012, 72, 1248-1261.	1.2	126
120	Secretory phospholipase A2 is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate, 2012, 72, 1140-1149.	1.2	32
121	miRNA-708 Control of CD44+ Prostate Cancer-Initiating Cells. Cancer Research, 2012, 72, 3618-3630.	0.4	117
122	Epigenetic markers of prostate cancer in plasma circulating DNA. Human Molecular Genetics, 2012, 21, 3619-3631.	1.4	50
123	A Review on the Clinical Utility of PSA in Cancer Prostate. Indian Journal of Surgical Oncology, 2012, 3, 120-129.	0.3	100
124	Commentary: eight ways to prevent cancer: a framework for effective prevention messages for the public. Cancer Causes and Control, 2012, 23, 601-608.	0.8	19
125	Risk-Based Prostate Cancer Screening. European Urology, 2012, 61, 652-661.	0.9	102
126	An Editorial Response to the USPTF. Journal of Men's Health, 2012, 9, 5-8.	0.1	2
127	Cancer screening in the United States, 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 129-142.	157.7	123
128	Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU International, 2012, 110, 353-362.	1.3	41
129	Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU International, 2012, 110, 1485-1490.	1.3	25
130	Patterns of prostate-specific antigen (PSA) testing in Australian men: the influence of family history. BJU International, 2012, 109, 64-70.	1.3	11
131	Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <math>\leq 2.5\text{ ng/mL}</math> and the risk of death. BJU International, 2012, 110, 1636-1641.	1.3	10
132	Updating risk prediction tools: A case study in prostate cancer. Biometrical Journal, 2012, 54, 127-142.	0.6	26
133	Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer. International Archive of Medicine, 2013, 6, 2.	1.2	1
134	Older Korean American Men's Prostate Cancer Screening Behavior: The Prime Role of Culture. Journal of Immigrant and Minority Health, 2013, 15, 1030-1037.	0.8	7



#	ARTICLE	IF	CITATIONS
135	Clinical significance of CD146 and latexin during different stages of thyroid cancer. <i>Molecular and Cellular Biochemistry</i> , 2013, 381, 95-103.	1.4	11
136	Pharmacogenetics in Primary Care: The Promise of Personalized Medicine and the Reality of Racial Profiling. <i>Culture, Medicine and Psychiatry</i> , 2013, 37, 226-235.	0.7	18
137	Screening for Prostate Cancer. , 2013, , 333-346.		2
138	Next Generation Screening Tests. , 2013, , 347-354.		0
139	A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 19.	1.5	10
140	Risk-Based Prostate Cancer Screening: Who and How?. <i>Current Urology Reports</i> , 2013, 14, 192-198.	1.0	14
141	Classifying the Reasons Men Consider to be Important in Prostate-Specific Antigen (PSA) Testing Decisions: Evaluating Risks, Lay Beliefs, and Informed Decisions. <i>Annals of Behavioral Medicine</i> , 2013, 46, 322-335.	1.7	3
142	MRI-guided core biopsy of the prostate in the supine position—introduction of a simplified technique using large-bore magnet systems. <i>European Radiology</i> , 2013, 23, 1415-1419.	2.3	9
143	When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. <i>World Journal of Urology</i> , 2013, 31, 365-369.	1.2	13
144	Clinical performance of serum prostate-specific antigen isoform [ $\alpha$ 2]proPSA (<sc>p2PSA</sc>) and its derivatives, %<sc>p2PSA</sc> and the prostate health index (<sc>PHI</sc>), in men with a family history of prostate cancer: results from a multicentre <sc>F</sc>uropean study, the <sc>PROMetheus</sc> project. <i>BJU International</i> , 2013, 112, 313-321.	1.3	93
145	Does obesity affect the accuracy of prostate-specific antigen (<sc>PSA</sc>) for predicting prostate cancer among men undergoing prostate biopsy. <i>BJU International</i> , 2013, 112, E265-71.	1.3	26
146	PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1522-1526.	0.8	35
147	Early Detection, PSA Screening, and Management of Overdiagnosis. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1091-1110.	0.9	9
148	Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure. <i>BMC Family Practice</i> , 2013, 14, 186.	2.9	5
149	Optical fibre probe NIR Raman measurements in ambient light and in combination with a tactile resonance sensor for possible cancer detection. <i>Analyst, The</i> , 2013, 138, 4029.	1.7	3
150	Combined application of information theory on laboratory results with classification and regression tree analysis: Analysis of unnecessary biopsy for prostate cancer. <i>Clinica Chimica Acta</i> , 2013, 415, 133-137.	0.5	1
151	Risk stratification in prostate cancer screening. <i>Nature Reviews Urology</i> , 2013, 10, 38-48.	1.9	97
152	Cancer of the Prostate, Testicles and Penis. , 2013, , 557-589.		0

#	ARTICLE	IF	CITATIONS
153	Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling. <i>Carcinogenesis</i> , 2013, 34, 406-414.	1.3	63
154	The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1464-1469.	0.8	3
155	Evaluation of Novel Formula of PSA, Age, Prostate Volume, and Race in Predicting Positive Prostate Biopsy Findings. <i>Urology</i> , 2013, 81, 602-606.	0.5	15
156	Prostate cancer risk prediction in a urology clinic in Mexico. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1085-1092.	0.8	6
157	Use of choline tracers in the prostate carcinoma management. <i>Medecine Nucleaire</i> , 2013, 37, 71-77.	0.2	0
158	Screening for prostate cancer: an updated review. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 101-108.	1.1	11
159	Cancer screening in the United States, 2013. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 87-105.	157.7	249
160	Prostate Cancer Screening In Men Ages 75 And Older Fell By 8 Percentage Points After Task Force Recommendation. <i>Health Affairs</i> , 2013, 32, 596-602.	2.5	34
161	Fully automated prostate magnetic resonance imaging and transrectal ultrasound fusion via a probabilistic registration metric. , 2013, 8671, .		15
162	Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 289-301.	12.5	207
163	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 295-302.	2.0	46
164	Multiparametric Magnetic Resonance Imaging of the Prostate. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2013, 21, 409-426.	0.6	14
165	Prostate Specific Antigen:The Past, Present and Future. <i>Current Urology</i> , 2013, 6, 175-178.	0.4	2
166	What is lacking in current decision aids on cancer screening?. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 193-214.	157.7	58
167	Screening for prostate cancer. <i>The Cochrane Library</i> , 2013, 2013, CD004720.	1.5	452
168	Prostate cancer screening in black men—new questions, few answers. <i>Cancer</i> , 2013, 119, 2206-2208.	2.0	2
169	The Impact of PSA Screening on Prostate Cancer Mortality and Overdiagnosis of Prostate Cancer in the United States. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 56-61.	1.7	40
171	A Community-Driven Intervention for Prostate Cancer Screening in African Americans. <i>Health Education and Behavior</i> , 2013, 40, 11-18.	1.3	13

#	ARTICLE	IF	CITATIONS
172	High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives. <i>Scandinavian Journal of Urology</i> , 2013, 47, 179-187.	0.6	10
173	Prostate-Specific Antigen Testing in Men Aged 40-64 Years: Impact of Publication of Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2013, 105, 743-745.	3.0	13
174	Does Prostate HistoScanning accurately identify prostate cancer, measure tumour volume and assess pathological stage prior to radical prostatectomy?. <i>Journal of Clinical Urology</i> , 2013, 6, 395-402.	0.1	8
175	Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. <i>Current Opinion in Oncology</i> , 2013, 25, 518-525.	1.1	24
176	The influence of family history on cognitive heuristics, risk perceptions, and prostate cancer screening behavior.. <i>Health Psychology</i> , 2013, 32, 1158-1169.	1.3	24
177	The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice. <i>Family Practice</i> , 2013, 30, 641-647.	0.8	5
178	Shared Decision Making in Prostate-Specific Antigen Testing. <i>Journal of Primary Care and Community Health</i> , 2013, 4, 67-74.	1.0	17
179	National Evidence on the Use of Shared Decision Making in Prostate-Specific Antigen Screening. <i>Annals of Family Medicine</i> , 2013, 11, 306-314.	0.9	83
180	Improving the Quality of Decision-Making Processes for Prostate Cancer Screening: Progress and Challenges. <i>JAMA Internal Medicine</i> , 2013, 173, 1713-4.	2.6	2
181	Assessment of Screenees' Knowledge on Prostate Cancer: Results of a Questionnaire Using the Fact Sheet. <i>Urologia Internationalis</i> , 2013, 91, 49-54.	0.6	3
182	Shared Decision Making in Prostate-Specific Antigen Testing With Men Older Than 70 Years. <i>Journal of the American Board of Family Medicine</i> , 2013, 26, 401-408.	0.8	13
183	Personalized Medicine in Screening for Malignant Disease: A Review of Methods and Applications. <i>Biomarker Insights</i> , 2013, 8, BMI.S11153.	1.0	9
184	Cancer Evaluation in Geriatric Population: A Single Institution Experience. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2013, 23, 28-33.	0.1	1
185	Attachment and Health Care Utilization Among Middle-Aged and Older African-Descent Men. <i>American Journal of Men's Health</i> , 2013, 7, 382-393.	0.7	6
186	Health and well-being among physicians. <i>Internal Medicine Journal</i> , 2013, 43, 1310-1315.	0.5	3
187	Severe lack of comprehension of common prostate health terms among low-income inner-city men. <i>Cancer</i> , 2013, 119, 3204-3211.	2.0	31
188	Genes, Race, and Culture in Clinical Care. <i>Medical Anthropology Quarterly</i> , 2013, 27, 253-271.	0.7	39
189	Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming. <i>Cancer Science</i> , 2013, 104, 1017-1026.	1.7	42

#	ARTICLE	IF	CITATIONS
190	Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 193-203.	2.0	19
191	Primary Care Physicians' Use of an Informed Decision-Making Process for Prostate Cancer Screening. <i>Annals of Family Medicine</i> , 2013, 11, 67-74.	0.9	47
192	Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians. <i>Annals of Internal Medicine</i> , 2013, 158, 761.	2.0	234
193	Prostate Cancer Treatment Choices. <i>Annals of Internal Medicine</i> , 2013, 159, 436.	2.0	0
194	Prostate Cancer Treatment Choices. <i>Annals of Internal Medicine</i> , 2013, 159, 435.	2.0	1
195	Limitations of Basing Screening Policies on Screening Trials. <i>Medical Care</i> , 2013, 51, 295-300.	1.1	63
196	Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 145.	2.0	144
197	Is Prostate-Specific Antigen Effective for Population Screening of Prostate Cancer? A Systematic Review. <i>Annals of Laboratory Medicine</i> , 2013, 33, 233-241.	1.2	21
198	Serum levels of Sex Hormone Binding Globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 793-799.	0.7	8
199	Can 3T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension?. <i>Canadian Urological Association Journal</i> , 2013, 7, 699.	0.3	32
200	African American Men's and Women's Perceptions of Clinical Trials Research: Focusing on Prostate Cancer among a High-Risk Population in the South. <i>Journal of Health Care for the Poor and Underserved</i> , 2013, 24, 1784-1800.	0.4	44
201	Future Prospects in the Diagnosis and Management of Localized Prostate Cancer. <i>Scientific World Journal</i> , The, 2013, 2013, 1-9.	0.8	6
202	The Role of Physiotherapy in the Pre and Post Treatment Interventions in Prostate Cancer Patients. , 2013, , .		0
203	A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. <i>Journal of Biomarkers</i> , 2014, 2014, 1-12.	1.0	10
204	Regulation of SRC Kinases by microRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1952-1963.	1.9	31
206	How should prostate specific antigen be interpreted?. <i>Turk Uroloji Dergisi</i> , 2014, 39, 188-193.	0.4	13
207	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	1.1	88
208	Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. <i>BMJ Open</i> , 2014, 4, e004895-e004895.	0.8	23

#	ARTICLE	IF	CITATIONS
209	A Simple Schema for Informed Decision Making About Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2014, 161, 441.	2.0	25
210	Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1349-1358.	1.1	8
211	Pre-Screening Age African-American Males: What Do They Know About Prostate Cancer Screening, Knowledge, and Risk Perceptions?. <i>Social Work in Health Care</i> , 2014, 53, 268-288.	0.8	14
212	Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men. <i>Psycho-Oncology</i> , 2014, 23, 404-411.	1.0	8
213	Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection. <i>BJU International</i> , 2014, 113, 535-540.	1.3	51
214	A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. <i>BJU International</i> , 2014, 113, E106-11.	1.3	14
215	Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. <i>BJU International</i> , 2014, 113, 77-83.	1.3	15
216	Patterns of cancer screening in primary care from 2005 to 2010. <i>Cancer</i> , 2014, 120, 253-261.	2.0	40
217	Prostate-specific antigen screening: A critical review of current research and guidelines. <i>Journal of the American Association of Nurse Practitioners</i> , 2014, 26, 574-581.	0.5	8
218	Screening for Prostate Cancer With the Prostate-Specific Antigen Test. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1143.	3.8	296
219	Physicians' Anxiety Due to Uncertainty and Use of Race in Medical Decision Making. <i>Medical Care</i> , 2014, 52, 728-733.	1.1	25
220	Cancer Screening Rates in Individuals With Different Life Expectancies. <i>JAMA Internal Medicine</i> , 2014, 174, 1558.	2.6	142
221	Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?. <i>Genetics in Medicine</i> , 2014, 16, 338-346.	1.1	24
222	What Do the Screening Trials Really Tell Us and Where Do We Go From Here?. <i>Urologic Clinics of North America</i> , 2014, 41, 223-228.	0.8	15
223	Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening. <i>Journal of Urology</i> , 2014, 192, 724-729.	0.2	37
224	Serum levels of 17- $\beta$ -estradiol are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 35.e9-35.e13.	0.8	2
225	International Perspectives on Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 237-247.	0.8	2
226	Perceptions of Prostate Cancer Fatalism and Screening Behavior Between United States-Born and Caribbean-Born Black Males. <i>Journal of Immigrant and Minority Health</i> , 2014, 16, 394-400.	0.8	27

#	ARTICLE	IF	CITATIONS
227	A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients. <i>BMC Urology</i> , 2014, 14, 8.	0.6	12
228	Physician Behaviors to Promote Informed Decisions for Prostate Cancer Screening: a National Research Network Study. <i>Journal of Cancer Education</i> , 2014, 29, 345-349.	0.6	3
229	STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 53.e23-53.e29.	0.8	48
230	Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 30-51.	157.7	167
231	The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer. <i>Tumor Biology</i> , 2014, 35, 5993-6002.	0.8	13
232	The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-specific Antigen Levels. <i>Academic Radiology</i> , 2014, 21, 578-589.	1.3	22
233	Metabolomic investigation of human diseases biomarkers by <sc>CE</sc> and <sc>LC</sc> coupled to <sc>MS</sc>. <i>Electrophoresis</i> , 2014, 35, 1285-1307.	1.3	19
234	Prostate Cancer Screening. <i>Primary Care - Clinics in Office Practice</i> , 2014, 41, 355-370.	0.7	7
235	Proteomics in investigation of cancer metastasis: Functional and clinical consequences and methodological challenges. <i>Proteomics</i> , 2014, 14, 426-440.	1.3	12
236	Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial. <i>Contemporary Clinical Trials</i> , 2014, 39, 327-334.	0.8	3
237	The cost implications of prostate cancer screening in the Medicare population. <i>Cancer</i> , 2014, 120, 96-102.	2.0	50
238	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.	157.7	324
239	Expected population impacts of discontinued prostate-specific antigen screening. <i>Cancer</i> , 2014, 120, 3519-3526.	2.0	90
240	Pathology Consultation on Prostate-Specific Antigen Testing. <i>American Journal of Clinical Pathology</i> , 2014, 142, 7-15.	0.4	4
241	Re: Prostate Biopsy for the Interventional Radiologist. <i>Journal of Urology</i> , 2014, 192, 765-767.	0.2	0
242	The complexity of PSA interpretation in clinical practice. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2014, 12, 323-327.	0.8	7
243	Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study. <i>BMC Family Practice</i> , 2014, 15, 121.	2.9	6
244	Prostate Biopsy for the Interventional Radiologist. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 675-684.	0.2	15

#	ARTICLE	IF	CITATIONS
245	Patient-reported Outcomes in Randomised Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical Decision Making. <i>European Urology</i> , 2014, 66, 416-427.	0.9	62
246	Decision Making and Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 257-266.	0.8	14
247	Counterpoint: Overdiagnosis in Breast Cancer Screening. <i>Journal of the American College of Radiology</i> , 2014, 11, 648-652.	0.9	13
248	Defining the level of evidence for technology adoption in the localized prostate cancer pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 924-930.	0.8	7
249	Evaluation of Systems-Oriented Public Health Interventions: Alternative Research Designs. <i>Annual Review of Public Health</i> , 2014, 35, 9-27.	7.6	122
250	Lack of Shared Decision Making in Cancer Screening Discussions. <i>American Journal of Preventive Medicine</i> , 2014, 47, 251-259.	1.6	87
251	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. <i>Annals of Internal Medicine</i> , 2014, 161, 104.	2.0	123
252	Online prostate cancer screening decision aid for at-risk men: A randomized trial.. <i>Health Psychology</i> , 2014, 33, 986-997.	1.3	22
253	Epigenetic regulation of <i>EFEMP1</i> in prostate cancer: biological relevance and clinical potential. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 2287-2297.	1.6	23
254	Prostate Cancer Deaths and Incident Cases Among American Indian/Alaska Native Men, 1999-2009. <i>American Journal of Public Health</i> , 2014, 104, S439-S445.	1.5	16
255	US Primary Care Physicians' Prostate Cancer Screening Practices. <i>Health Services Research and Managerial Epidemiology</i> , 2014, 1, 233339281456290.	0.5	2
256	The ONCOTYROL Prostate Cancer Outcome and Policy Model. <i>Medical Decision Making</i> , 2015, 35, 758-772.	1.2	8
257	Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review. <i>Psycho-Oncology</i> , 2015, 24, 1303-1315.	1.0	30
258	Prostate-specific antigen-based prostate cancer screening: Past and future. <i>International Journal of Urology</i> , 2015, 22, 524-532.	0.5	59
259	Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications. <i>Oncology Letters</i> , 2015, 9, 2757-2761.	0.8	47
260	Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. <i>Asian Journal of Urology</i> , 2015, 2, 114-122.	0.5	2
261	MP42-19 DECISION AIDS FOR LOCALIZED PROSTATE CANCER TREATMENT CHOICE: SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Journal of Urology</i> , 2015, 193, .	0.2	1
262	Why and how would we implement a lung cancer screening program?. <i>Public Health Reviews</i> , 2015, 36, 10.	1.3	6

#	ARTICLE	IF	CITATIONS
263	Prostate cancer survivors' beliefs about screening and treatment decision-making experiences in an era of controversy. <i>Psycho-Oncology</i> , 2015, 24, 1073-1079.	1.0	18
264	Getting Black Men to Undergo Prostate Cancer Screening. <i>American Journal of Men's Health</i> , 2015, 9, 385-396.	0.7	40
265	Discussions with healthcare providers about prostate-specific antigen testing: evidence from the Behavioral Risk Factor Surveillance System in the USA. <i>Journal of Pharmaceutical Health Services Research</i> , 2015, 6, 47-52.	0.3	2
266	The Case for Tailored Prostate Cancer Screening: An NCCN Perspective. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1576-1583.	2.3	16
267	Multiparametric Prostate Magnetic Resonance Imaging at 3 T. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 674-680.	0.5	13
268	When Should 99mTc Bone Scintigraphy Be Performed in cT1N0 Non-Small Cell Lung Cancer Patients?. <i>Medicine (United States)</i> , 2015, 94, e2309.	0.4	10
269	Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. <i>PLoS ONE</i> , 2015, 10, e0128235.	1.1	13
270	Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0143283.	1.1	117
271	Does imprint cytology improve the accuracy of transrectal prostate needle biopsy?. <i>Diagnostic Cytopathology</i> , 2015, 43, 91-97.	0.5	1
272	American Cancer Society Colorectal Cancer Survivorship Care Guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 427-455.	157.7	314
273	The channel capacity of a diagnostic test as a function of test sensitivity and test specificity. <i>Statistical Methods in Medical Research</i> , 2015, 24, 1044-1052.	0.7	8
274	Dynamic Light Scattering Coupled with Gold Nanoparticle Probes as a Powerful Sensing Technique for Chemical and Biological Target Detection. <i>ACS Symposium Series</i> , 2015, , 157-179.	0.5	6
275	Exploring automatic prostate histopathology image gleason grading via local structure modeling. , 2015, 2015, 2649-52.		18
276	Impact of age, race and socio-economic status on temporal trends in late-stage prostate cancer diagnosis in Florida. <i>Spatial Statistics</i> , 2015, 14, 321-337.	0.9	12
277	Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 315-319.	0.8	6
278	Screening for Cancer: When to Stop?. <i>Medical Clinics of North America</i> , 2015, 99, 249-262.	1.1	11
279	Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 30-54.	157.7	299
280	Feasibility Study of Engaging Barbershops for Prostate Cancer Education in Rural African-American Communities. <i>Journal of Cancer Education</i> , 2015, 30, 623-628.	0.6	18



#	ARTICLE	IF	CITATIONS
281	The Relationship Between Education and Prostate-Specific Antigen Testing Among Urban African American Medicare Beneficiaries. <i>Journal of Racial and Ethnic Health Disparities</i> , 2015, 2, 176-183.	1.8	10
282	Decisional outcomes following use of an interactive web-based decision aid for prostate cancer screening. <i>Translational Behavioral Medicine</i> , 2015, 5, 189-197.	1.2	8
283	An age-“period” cohort analysis of cancer incidence among the oldest old, Utah 1973-2002. <i>Population Studies</i> , 2015, 69, 7-22.	1.1	18
285	Responses to a Decision Aid on Prostate Cancer Screening in Primary Care Practices. <i>American Journal of Preventive Medicine</i> , 2015, 49, 520-525.	1.6	30
286	Earlier prostate-specific antigen testing in African American men-“Clinical support for the recommendation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 330.e9-330.e17.	0.8	11
287	National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-“Based Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2416-2423.	0.8	184
288	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 525-530.e3.	0.9	23
289	A Randomized Controlled Effectiveness Trial for PSA Screening Decision Support Interventions in Two Primary Care Settings. <i>Journal of General Internal Medicine</i> , 2015, 30, 810-816.	1.3	18
290	Video-“based educational tool improves patient comprehension of common prostate health terminology. <i>Cancer</i> , 2015, 121, 733-740.	2.0	48
291	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. <i>Journal of Urology</i> , 2015, 193, 1519-1524.	0.2	90
292	Prostate-specific antigen-based screening: controversy and guidelines. <i>BMC Medicine</i> , 2015, 13, 61.	2.3	84
293	Gold Nanoparticle-Enabled Blood Test for Early Stage Cancer Detection and Risk Assessment. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 6819-6827.	4.0	125
294	Decision aids for localized prostate cancer treatment choice: Systematic review and meta-“analysis. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 239-251.	157.7	115
295	Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 637-652.	1.1	60
296	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. <i>European Urology</i> , 2015, 68, 756-765.	0.9	57
297	Multiattribute probabilistic prostate elastic registration (MAPPER): Application to fusion of ultrasound and magnetic resonance imaging. <i>Medical Physics</i> , 2015, 42, 1153-1163.	1.6	12
298	Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps. <i>Expert Review of Proteomics</i> , 2015, 12, 651-667.	1.3	9
299	A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. <i>Translational Psychiatry</i> , 2015, 5, e614-e614.	2.4	58

#	ARTICLE	IF	CITATIONS
300	Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. <i>American Journal of Health Promotion</i> , 2015, 29, 393-401.	0.9	9
301	Prostate Cancer in Elderly Men. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 615-629.	1.0	17
302	Informed Decision-Making and Breast Cancer Screening. <i>Journal of Medical Screening</i> , 2015, 22, 165-167.	1.1	13
303	NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 287-296.	1.5	8
304	Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2054.	3.8	382
305	Increased Levels of $\beta$ -catenin, LEF-1, and HPA-1 Correlate with Poor Prognosis for Acral Melanoma with Negative <i>BRAF</i> and <i>NRAS</i> Mutation in <i>BRAF</i> Exons 11 and 15 and <i>NRAS</i> Exons 1 and 2. <i>DNA and Cell Biology</i> , 2015, 34, 69-77.	0.9	20
306	Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers. <i>Chemical Communications</i> , 2015, 51, 4564-4567.	2.2	21
307	Cancer beliefs and cancer screening behaviors among low income Chinese immigrants – Implications for culturally relevant interventions. <i>Journal of Nursing Education and Practice</i> , 2016, 6, .	0.1	1
308	Evolving Recommendations on Prostate Cancer Screening. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e80-e87.	1.8	8
309	Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia. <i>Disease Markers</i> , 2016, 2016, 1-12.	0.6	20
310	Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection. <i>SpringerPlus</i> , 2016, 5, 1484.	1.2	4
311	Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. <i>International Journal of Cancer</i> , 2016, 138, 2221-2230.	2.3	11
312	<i>NCOA2</i> is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 365-374.	1.5	14
313	Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies. <i>International Journal of Cancer</i> , 2016, 138, 2368-2382.	2.3	59
314	Facilitating Shared Decision Making About Prostate Cancer Screening Among African American Men. <i>Oncology Nursing Forum</i> , 2016, 43, 86-92.	0.5	12
315	Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: a cross-sectional study. <i>BMJ Open</i> , 2016, 6, e011467.	0.8	6
316	Identifying hotspots in five year survival electronic health records of older adults. , 2016, , .		2
317	Prostate Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. <i>Translational Oncology</i> , 2016, 9, 575-582.	1.7	12

#	ARTICLE	IF	CITATIONS
318	Population-based screening for cancer: hope and hype. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 550-565.	12.5	98
319	De Novo Malignancies After Transplantation. <i>Medical Clinics of North America</i> , 2016, 100, 551-567.	1.1	45
320	Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative. <i>European Urology</i> , 2016, 70, 854-861.	0.9	11
321	Predictors of prostate cancer screening using Andersen's Behavioral Model of Health Services Use. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 529.e9-529.e14.	0.8	21
322	The cancer registry as a cancer control tool. <i>Cancer</i> , 2016, 122, 1343-1345.	2.0	2
323	Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 95-114.	157.7	198
324	The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 359-369.	157.7	88
325	Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. <i>BJU International</i> , 2016, 117, E29-35.	1.3	33
326	Familial prostate cancer. <i>Seminars in Oncology</i> , 2016, 43, 560-565.	0.8	49
327	Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States. <i>Urology</i> , 2016, 97, 111-117.	0.5	15
328	Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review. <i>EBioMedicine</i> , 2016, 10, 164-173.	2.7	43
329	Retrospective chart analysis of incidental findings detected by <sup>18</sup> F-fluorodeoxyglucose-PET/CT in patients with cutaneous malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 807-816.	0.4	8
330	Retrospektive Analyse von Zufallsbefunden, die bei Patienten mit kutanem malignem Melanom durch <sup>18</sup> F-Fluorodeoxyglucose-PET/CT erhoben wurden. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 807-817.	0.4	7
331	Overexpression of ribosomal L1 domain containing 1 is associated with an aggressive phenotype and a poor prognosis in patients with prostate cancer. <i>Oncology Letters</i> , 2016, 11, 2839-2844.	0.8	13
332	Prostate Cancer Care Before and After Medicare Eligibility. <i>Inquiry (United States)</i> , 2016, 53, 004695801664729.	0.5	2
333	Prostate Specific Antigen. <i>Home Health Care Management and Practice</i> , 2016, 28, 187-190.	0.4	0
334	Recent Advances of Biochemical Analysis. , 2016, , 357-375.		4
335	The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 839-852.	1.5	22

#	ARTICLE	IF	CITATIONS
336	Multi-sequence texture analysis in classification of in vivo MR images of the prostate. <i>Biocybernetics and Biomedical Engineering</i> , 2016, 36, 537-552.	3.3	7
337	Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey. <i>Journal of Cancer Education</i> , 2016, 31, 693-701.	0.6	43
338	PSA and beyond: alternative prostate cancer biomarkers. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 97-106.	2.1	207
339	Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. <i>World Journal of Urology</i> , 2016, 34, 1107-1113.	1.2	4
340	Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. <i>Urology</i> , 2016, 90, 32-38.	0.5	8
341	Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities. <i>Preventive Medicine</i> , 2016, 82, 83-91.	1.6	38
342	Shared Decision Making – Finding the Sweet Spot. <i>New England Journal of Medicine</i> , 2016, 374, 104-106.	13.9	132
343	Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995–2012. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 259-263.	1.1	32
344	Knowledge and values for cancer screening decisions: Results from a national survey. <i>Patient Education and Counseling</i> , 2016, 99, 624-630.	1.0	12
345	Detection, quantification, and profiling of PSA: current microarray technologies and future directions. <i>RSC Advances</i> , 2016, 6, 7599-7609.	1.7	11
346	A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers. <i>Biomarkers</i> , 2016, 21, 387-403.	0.9	4
347	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. <i>Journal of Urology</i> , 2016, 195, 913-918.	0.2	32
348	The use of a gas chromatography-sensor system combined with advanced statistical methods, towards the diagnosis of urological malignancies. <i>Journal of Breath Research</i> , 2016, 10, 017106.	1.5	31
349	The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 296-302.	0.8	22
350	Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening. <i>Journal of Urology</i> , 2016, 195, 66-73.	0.2	73
351	Patient–Provider Communication About Prostate Cancer Screening and Treatment. <i>American Journal of Men's Health</i> , 2017, 11, 134-146.	0.7	19
352	Experiences of Uncertainty in Men With an Elevated PSA. <i>American Journal of Men's Health</i> , 2017, 11, 24-34.	0.7	14
353	Barbershop Prostate Cancer Education. <i>American Journal of Men's Health</i> , 2017, 11, 116-125.	0.7	3

#	ARTICLE	IF	CITATIONS
354	Determination of amino acids in urine of patients with prostate cancer and benign prostate growth. <i>European Journal of Cancer Prevention</i> , 2017, 26, 131-134.	0.6	17
355	Predictors of prostate cancer screening intention among older men in Jordan. <i>International Journal of Urological Nursing</i> , 2017, 11, 31-41.	0.1	8
356	Is prostate cancer stage migration continuing for black men in the PSA era?. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 210-215.	2.0	7
357	Knowledge of Prostate Cancer and Screening Among Young Multiethnic Black Men. <i>American Journal of Men's Health</i> , 2017, 11, 1008-1018.	0.7	22
359	Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 100-121.	157.7	529
360	Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 460.e9-460.e20.	0.8	22
361	Screening for prostate cancer. <i>Seminars in Oncology</i> , 2017, 44, 47-56.	0.8	20
363	Recent Patterns of Prostate-Specific Antigen Testing for Prostate Cancer Screening in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1040.	2.6	39
364	Is prostate cancer different in black men? Answers from 3 natural history models. <i>Cancer</i> , 2017, 123, 2312-2319.	2.0	100
365	Comparative effectiveness of prostate cancer treatments for patient-centered outcomes. <i>Medicine (United States)</i> , 2017, 96, e6790.	0.4	18
367	MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. <i>Oncogene</i> , 2017, 36, 2667-2679.	2.6	38
368	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. <i>Annals of Oncology</i> , 2017, 28, 1098-1104.	0.6	42
369	What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e977-e985.	0.9	4
370	Updated Review of Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1192-1208.	1.1	64
371	Androgen receptor and miR-206 regulation in prostate cancer. <i>Transcription</i> , 2017, 8, 313-327.	1.7	15
372	<i>BRCA</i> -associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. <i>Radiographics</i> , 2017, 37, 1005-1023.	1.4	56
373	Prevention of Prostate Cancer Morbidity and Mortality. <i>Medical Clinics of North America</i> , 2017, 101, 787-806.	1.1	115
374	Expression of full-length HER2 protein in Sf 9 insect cells and its presentation on the surface of budded virus-like particles. <i>Protein Expression and Purification</i> , 2017, 136, 27-38.	0.6	14

#	ARTICLE	IF	CITATIONS
375	Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 136, e348-e392.	1.6	147
376	Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation. <i>Cancer</i> , 2017, 123, 3875-3878.	2.0	1
377	Prevalence and associations of general practitioners'™ ordering of 'non-symptomatic' prostate-specific antigen tests: A cross-sectional analysis. <i>International Journal of Clinical Practice</i> , 2017, 71, e12998.	0.8	3
379	Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. <i>Radiology</i> , 2017, 285, 493-505.	3.6	197
380	Editorial Comment. <i>Urology</i> , 2017, 104, 129-130.	0.5	0
381	Cancer Screening in the Elderly. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 246-253.	1.0	34
382	Nanomaterial-based biosensors for detection of prostate specific antigen. <i>Mikrochimica Acta</i> , 2017, 184, 3049-3067.	2.5	94
383	Development of carbon-graphene-based aptamer biosensor for EN2 protein detection. <i>Analytical Biochemistry</i> , 2017, 534, 99-107.	1.1	40
384	Shared decision making as part of value based care: New U.S. policies challenge our readiness. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2017, 123-124, 104-108.	0.7	23
385	Single-step homogeneous immunoassay for detecting prostate-specific antigen using dual-color light scattering of metal nanoparticles. <i>Analyst, The</i> , 2017, 142, 3484-3491.	1.7	13
386	Barbershop Prostate Cancer Education: Factors Associated With Client Knowledge. <i>American Journal of Men's Health</i> , 2017, 11, 1415-1425.	0.7	7
387	Urinary <sc>microRNAs</sc> for prostate cancer diagnosis, prognosis, and treatment response: are we there yet?. <i>Wiley Interdisciplinary Reviews RNA</i> , 2017, 8, e1438.	3.2	18
388	Risk factors for metastatic prostate cancer: A sentinel event case series. <i>Prostate</i> , 2017, 77, 1366-1372.	1.2	2
390	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2017, , 883-923.		0
391	The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 424-429.	2.0	19
392	Benefits and harms of prostate cancer screening ' predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	1.2	12
393	Imaging on nodal staging of prostate cancer. <i>Future Oncology</i> , 2017, 13, 551-565.	1.1	2
394	Prostate and Colorectal Cancer Screening Uptake among US and Foreign-Born Males: Evidence from the 2015 NHIS Survey. <i>Journal of Community Health</i> , 2017, 42, 612-623.	1.9	9

#	ARTICLE	IF	CITATIONS
395	Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. <i>Cancer</i> , 2017, 123, 583-591.	2.0	15
396	Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and <scp>PSA</scp> level subgroups: A qualitative study. <i>Health Expectations</i> , 2017, 20, 779-787.	1.1	4
397	Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?. <i>European Journal of Epidemiology</i> , 2017, 32, 511-520.	2.5	2
398	The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race. <i>Journal of the National Medical Association</i> , 2017, 109, 49-54.	0.6	4
399	Use of Age and Medical Comorbidity to Assess Long-term Other-cause Mortality Risk in a Cohort of Men Undergoing Prostate Biopsy at an Academic Medical Center. <i>Urology</i> , 2017, 100, 169-174.	0.5	0
400	Impact of 2012 USPSTF Screening PSA Guideline Statement: Changes in Primary Care Provider Practice Patterns and Attitudes. <i>Urology Practice</i> , 2017, 4, 126-131.	0.2	5
401	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 222-227.	1.1	33
402	Urologists' Current Practices in Screening and Treating Men With a Family History of Prostate Cancer. <i>Urology</i> , 2017, 99, 180-185.	0.5	8
403	Determinants of behavioral intentions to screen for prostate cancer in Omani men. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2017, 4, 348-355.	0.7	8
404	Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 246-253.	1.0	13
405	Social Networks Across Common Cancer Types. <i>Advances in Cancer Research</i> , 2017, 133, 95-128.	1.9	9
406	Update on Screening for Urological Malignancies. <i>Rambam Maimonides Medical Journal</i> , 2017, 8, e0041.	0.4	7
407	Ultrasound Elastography: Review of Techniques and Clinical Applications. <i>Theranostics</i> , 2017, 7, 1303-1329.	4.6	1,103
408	Gastrin-releasing peptide receptor-targeted gadolinium oxide-based multifunctional nanoparticles for dual magnetic resonance/fluorescent molecular imaging of prostate cancer. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6787-6797.	3.3	14
409	Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer. <i>Molecular Cancer</i> , 2017, 16, 160.	7.9	41
410	Metastatic prostate cancer in the modern era of PSA screening. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 416-421.	0.7	1
411	Accuracy of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate cancer: systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 77975-77989.	0.8	10
412	Prostate cancer prediction using the random forest algorithm that takes into account transrectal ultrasound findings, age, and serum levels of prostate-specific antigen. <i>Asian Journal of Andrology</i> , 2017, 19, 586.	0.8	33

#	ARTICLE	IF	CITATIONS
413	Screening and Treating Prostate Cancer in the Older Patient: Decision Making Across the Clinical Spectrum. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 370-381.	1.8	3
414	Developing DNA methylation-based diagnostic biomarkers. Journal of Genetics and Genomics, 2018, 45, 87-97.	1.7	41
415	An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen. Analytical Chemistry, 2018, 90, 4414-4421.	3.2	54
416	Dielectrophoresis-based microfluidic platforms for cancer diagnostics. Biomicrofluidics, 2018, 12, 011503.	1.2	48
417	Prostate cancer screening: Beliefs and practices of the Brazilian physicians with different specialties. Journal of Evaluation in Clinical Practice, 2018, 24, 508-513.	0.9	2
418	The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis. Urology, 2018, 117, 108-114.	0.5	12
420	Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiologic Clinics of North America, 2018, 56, 187-196.	0.9	13
421	Factors Influencing Prostate Specific Antigen Testing in the United States. Urology Practice, 2018, 5, 438-443.	0.2	1
422	Stochastic Modeling of Temporal Enhanced Ultrasound: Impact of Temporal Properties on Prostate Cancer Characterization. IEEE Transactions on Biomedical Engineering, 2018, 65, 1798-1809.	2.5	4
423	Leveraging the Family Influence of Women in Prostate Cancer Efforts Targeting African American Men. Journal of Racial and Ethnic Health Disparities, 2018, 5, 820-830.	1.8	6
424	Prostate cancer screening: And the pendulum swings. Cancer, 2018, 124, 2890-2892.	2.0	2
425	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.4	153
426	Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study. American Journal of Roentgenology, 2018, 211, 114-120.	1.0	13
427	Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States. Annals of Family Medicine, 2018, 16, 139-144.	0.9	21
428	Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2018, 142, 1106-1112.	1.2	11
429	Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 339-347.	0.6	3
430	A Survey of the Knowledge of African-American Women About Prostate Cancer Screening. Journal of Cancer Education, 2018, 33, 1115-1119.	0.6	5
431	The role of the affect heuristic and cancer anxiety in responding to negative information about medical tests. Psychology and Health, 2018, 33, 292-312.	1.2	10



#	ARTICLE	IF	CITATIONS
432	Near infrared chemo-responsive dye intermediaries spectra-based in-situ quantification of volatile organic compounds. <i>Sensors and Actuators B: Chemical</i> , 2018, 254, 597-602.	4.0	34
433	Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. <i>Prostate</i> , 2018, 78, 48-53.	1.2	47
434	Individualized Approach to Cancer Screening in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2018, 34, 11-23.	1.0	14
435	The accuracy of patients'™ perceptions of the risks associated with localised prostate cancer treatments. <i>BJU International</i> , 2018, 121, 405-414.	1.3	15
436	Survival outcomes in elderly men undergoing radical prostatectomy in Australia. <i>ANZ Journal of Surgery</i> , 2018, 88, E189-E193.	0.3	1
437	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 954-960.	0.2	11
438	MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer. <i>Radiologia Medica</i> , 2018, 123, 227-234.	4.7	20
439	Prostate Cancer Screening in Early Medicaid Expansion States. <i>Journal of Urology</i> , 2018, 199, 81-88.	0.2	28
440	Rastreamento populacional para o c�ncel de pr�stata: mais riscos que benef�cios. <i>Physis</i> , 2018, 28, .	0.1	4
441	Driving behaviors associated with emergency service vehicle crashes in the U.S. fire service. <i>Traffic Injury Prevention</i> , 2018, 19, 849-855.	0.6	12
442	CAV3.1 knockdown suppresses cell proliferation, migration and invasion of prostate cancer cells by inhibiting AKT. <i>Cancer Management and Research</i> , 2018, Volume 10, 4603-4614.	0.9	12
443	Una mirada global y actualizada del c�ncel de pr�stata. <i>Revista Facultad De Medicina</i> , 2018, 66, 429-437.	0.0	2
444	MicroRNAs Role in Prostate Cancer. <i>Methods in Molecular Biology</i> , 2018, 1856, 103-117.	0.4	16
445	Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 297-316.	157.7	433
446	Prostate Cancer Screening Trends After United States Preventative Services Task Force Guidelines in an Underserved Population. <i>Health Equity</i> , 2018, 2, 55-61.	0.8	10
447	Medical Maximizing-Minimizing Preferences Predict Responses to Information about Prostate-Specific Antigen Screening. <i>Medical Decision Making</i> , 2018, 38, 708-718.	1.2	22
448	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
449	The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3883-3889.	1.0	4

#	ARTICLE	IF	CITATIONS
450	A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. <i>Cancer Medicine</i> , 2018, 7, 4773-4780.	1.3	20
451	Editorial Comment. <i>Urology</i> , 2018, 118, 125-126.	0.5	0
453	A Supervised Learning Tool for Prostate Cancer Foci Detection and Aggressiveness Identification using Multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging. <i>Cancer Informatics</i> , 2018, 17, 117693511878626.	0.9	3
454	Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use. <i>Journal of the National Medical Association</i> , 2018, 110, 491-500.	0.6	6
455	Current guidelines for prostate cancer screening: A systematic review and minimal core proposal. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 290-296.	0.3	5
456	Implications of the New USPSTF Prostate Cancer Screening Recommendation "Attaining Equipoise." <i>JAMA Internal Medicine</i> , 2018, 178, 889.	2.6	4
457	Proteoform Analysis to Fulfill Unmet Clinical Needs and Reach Global Standardization of Protein Measurands in Clinical Chemistry Proteomics. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 487-497.	0.7	14
458	SVM for FT-MIR prostate cancer classification: An alternative to the traditional methods. <i>Journal of Chemometrics</i> , 2018, 32, e3075.	0.7	10
459	African American Women's Involvement in Promoting Informed Decision-Making for Prostate Cancer Screening Among Their Partners/Spouses. <i>American Journal of Men's Health</i> , 2018, 12, 884-893.	0.7	14
460	Primary Care Providers' Intended Use of Decision Aids for Prostate-Specific Antigen Testing for Prostate Cancer Screening. <i>Journal of Cancer Education</i> , 2019, 34, 666-670.	0.6	7
461	A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. <i>Prostate</i> , 2019, 79, 1705-1714.	1.2	24
462	Are decision aids leading to shared prostate cancer screening decisions among African-American men?: iDecide. <i>Cancer Causes and Control</i> , 2019, 30, 713-719.	0.8	7
463	Evaluation of Implementation Outcomes After Initiation of a Shared Decision-making Program for Men With Prostate Cancer. <i>Urology</i> , 2019, 132, 94-100.	0.5	6
464	How Do Older Adults Consider Age, Life Expectancy, Quality of Life, and Physician Recommendations When Making Cancer Screening Decisions? Results from a National Survey Using a Discrete Choice Experiment. <i>Medical Decision Making</i> , 2019, 39, 621-631.	1.2	11
465	Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine. <i>British Journal of Cancer</i> , 2019, 121, 857-868.	2.9	74
466	Essential attributes of an acceptable in vitro diagnostic test. , 2019, , 97-115.		0
467	Effects of the Training About Prostate Cancer and Screening Methods on Knowledge Level. <i>Nursing Science Quarterly</i> , 2019, 32, 333-339.	0.3	1
468	A review of optimal prostate biopsy: indications and techniques. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721987007.	0.9	36

#	ARTICLE	IF	CITATIONS
469	Cribado del cncer de prstata con antgeno especfico prosttico en varones mayores de 75 aos. Medicina Clnica, 2019, 152, 237-240.	0.3	3
470	Elastodiagnosis of diseases: A review. Extreme Mechanics Letters, 2019, 27, 102-123.	2.0	19
471	Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa. World Journal of Urology, 2019, 37, 2091-2097.	1.2	5
472	&lt;p&gt;Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 3079-3097.	0.9	12
473	Prostate cancer screening: guidelines review and laboratory issues. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1474-1487.	1.4	31
474	Projected oropharyngeal carcinoma incidence among middleged US men. Head and Neck, 2019, 41, 3226-3234.	0.9	33
475	Highly sensitive biosensor based on graphenepoly (3-aminobenzoic acid) modified electrodes and porous-hollowed-silver-gold nanoparticle labelling for prostate cancer detection. Sensors and Actuators B: Chemical, 2019, 296, 126657.	4.0	46
476	Can expressed prostatic secretions affect prostate biopsy decision of urologist?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 246-252.	0.7	0
477	Prostate biopsy: when and how to perform. Clinical Radiology, 2019, 74, 853-864.	0.5	31
478	Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study. BMC Urology, 2019, 19, 23.	0.6	6
479	Prostate-specific antigen screening for prostate cancer in males older than 75 years. Medicina Clnica (English Edition), 2019, 152, 237-240.	0.1	0
480	&lt;p&gt;Research status and progress of the RNA or protein biomarkers for prostate cancer&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 2123-2136.	1.0	9
481	Cancer fatalism and adherence to national cancer screening guidelines: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Cancer Epidemiology, 2019, 60, 39-45.	0.8	17
482	Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2019, 69, 184-210.	157.7	448
483	Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma. Scientific Reports, 2019, 9, 5168.	1.6	15
484	Association between human papillomavirus infection and prostate cancer: A global systematic review and metaanalysis. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e59-e67.	0.7	39
485	Care and Cancer Screening of the Transgender Population. Journal of Women's Health, 2019, 28, 761-768.	1.5	18
487	Would You Recommend Prostate-Specific Antigen Screening for This Patient?. Annals of Internal Medicine, 2019, 170, 770.	2.0	1

#	ARTICLE	IF	CITATIONS
488	Translation and cultural adaptation of the web and printed versions of a decision aid to support men's prostate cancer screening choice: a protocol. <i>BMJ Open</i> , 2019, 9, e028938.	0.8	2
489	Development and Psychometric Properties of a Prostate Cancer Knowledge Scale for African American Men. <i>American Journal of Men's Health</i> , 2019, 13, 155798831989245.	0.7	3
490	Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health. <i>Medicine (United States)</i> , 2019, 98, e17451.	0.4	21
491	Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men. <i>JAMA Oncology</i> , 2019, 5, 60.	3.4	40
492	Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 515-522.	0.9	22
493	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. <i>European Urology</i> , 2019, 75, 570-578.	0.9	521
494	A blueprint for cancer screening and early detection: Advancing screening's contribution to cancer control. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 50-79.	157.7	84
495	Influence of Age, Health, and Function on Cancer Screening in Older Adults with Limited Life Expectancy. <i>Journal of General Internal Medicine</i> , 2019, 34, 110-117.	1.3	18
496	Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies. <i>Cancer</i> , 2019, 125, 843-853.	2.0	23
497	Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 632-638.	2.3	3
498	Exnovation of Low Value Care: A Decade of Prostate-specific Antigen Screening Practices. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 29-36.	1.3	9
499	The Effect of Educational Program Based on PRECEDE Model in Promoting Prostate Cancer Screening in a Sample of Iranian Men. <i>Journal of Cancer Education</i> , 2019, 34, 161-172.	0.6	23
500	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. <i>European Urology Focus</i> , 2020, 6, 273-279.	1.6	8
501	Decision models for distinguishing between clinically insignificant and significant tumors in prostate cancer biopsies: an application of Bayes' Theorem to reduce costs and improve outcomes. <i>Health Care Management Science</i> , 2020, 23, 102-116.	1.5	2
502	Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. <i>European Urology</i> , 2020, 77, 38-52.	0.9	699
503	Prostate MRI-TRUS fusion biopsy: a review of the state of the art procedure. <i>Abdominal Radiology</i> , 2020, 45, 2176-2183.	1.0	16
504	PreView: a Randomized Trial of a Multi-site Intervention in Diverse Primary Care to Increase Rates of Age-Appropriate Cancer Screening. <i>Journal of General Internal Medicine</i> , 2020, 35, 449-456.	1.3	4
505	Chemically Modified Natural Polymer-Based Theranostic Nanomedicines: Are They the Golden Gate toward a <i>de Novo</i> Clinical Approach against Cancer?. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 134-166.	2.6	32

#	ARTICLE	IF	CITATIONS
506	Age dependence of modern clinical risk groups for localized prostate cancer—A population-based study. <i>Cancer</i> , 2020, 126, 1691-1699.	2.0	25
507	Screening for Prostate Cancer. <i>Medical Clinics of North America</i> , 2020, 104, 1051-1062.	1.1	79
508	Results of the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 430-436.	0.2	0
509	Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know. <i>British Journal of Radiology</i> , 2020, 93, 20200484.	1.0	0
510	Risk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study. <i>Cancer</i> , 2020, 126, 4371-4378.	2.0	4
511	A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers. <i>Cancers</i> , 2020, 12, 2017.	1.7	18
512	MiR-93/miR-375: Diagnostic Potential, Aggressiveness Correlation and Common Target Genes in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5667.	1.8	13
513	Factors Associated with Cancer Screening Among Hopi Men. <i>Journal of Cancer Education</i> , 2022, 37, 915-923.	0.6	3
514	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 383-400.	0.4	4
515	Heart transplantation in patients with localized prostate cancer—Are we denying a life-saving therapy due to an indolent tumor?. <i>Clinical Transplantation</i> , 2020, 34, e14080.	0.8	2
516	Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe. <i>Infectious Agents and Cancer</i> , 2020, 15, 59.	1.2	3
517	Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. <i>Preventive Medicine Reports</i> , 2020, 20, 101174.	0.8	7
518	Translation and cultural adaptation of a prostate cancer screening decision aid: a qualitative study in Portugal. <i>BMJ Open</i> , 2020, 10, e034384.	0.8	4
519	Predictors of prostate-specific antigen testing in men aged 55 years: A cross-sectional study based on patient-reported outcomes. <i>International Journal of Urology</i> , 2020, 27, 711-718.	0.5	2
520	Albuminuria, Kidney Function, and Cancer Risk in the Community. <i>American Journal of Epidemiology</i> , 2020, 189, 942-950.	1.6	26
521	Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. <i>Cancer Prevention Research</i> , 2020, 13, 367-376.	0.7	3
522	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
523	Factors associated with appropriate and low-value PSA testing. <i>Cancer Epidemiology</i> , 2020, 66, 101724.	0.8	2

#	ARTICLE	IF	CITATIONS
524	The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial. <i>PLoS Medicine</i> , 2020, 17, e1003033.	3.9	6
525	Self-efficacy and importance of participation reasons as predictors for prostate cancer screening intention in African American men. <i>Ethnicity and Health</i> , 2022, 27, 316-328.	1.5	4
526	Magnetic Resonance Imaging of Prostate Adenocarcinoma. <i>Topics in Magnetic Resonance Imaging</i> , 2020, 29, 17-30.	0.7	4
527	Cancer Progress and Priorities: Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 267-277.	1.1	25
528	Prostate-Specific Antigen Test Utilization in a Major Canadian City. <i>American Journal of Clinical Pathology</i> , 2020, 153, 776-780.	0.4	2
529	SEOM clinical guideline for secondary prevention (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 187-192.	1.2	7
530	In silico studies of piperazine derivatives as potent anti-proliferative agents against PC-3 prostate cancer cell lines. <i>Heliyon</i> , 2020, 6, e03273.	1.4	6
531	Screening Tools Used by Clinical Pharmacists to Identify Elderly Patients at Risk of Drug-Related Problems on Hospital Admission: A Systematic Review. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 64.	0.6	9
532	Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 77-80.	2.0	23
533	Comparing a new risk prediction model with prostate cancer risk calculator apps in a Taiwanese population. <i>World Journal of Urology</i> , 2021, 39, 797-802.	1.2	3
534	A discussion on controversies and ethical dilemmas in prostate cancer screening. <i>Journal of Medical Ethics</i> , 2021, 47, 152-158.	1.0	11
535	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e12-e16.	0.9	6
536	Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. <i>Cancer</i> , 2021, 127, 249-256.	2.0	19
537	Is 99m Tc bone scintigraphy necessary in the preoperative workup for patients with cT1N0 subsolid lung cancer? A prospective multicenter cohort study. <i>Thoracic Cancer</i> , 2021, 12, 415-419.	0.8	2
538	Noninvasive Precision Screening of Prostate Cancer by Urinary Multimarker Sensor and Artificial Intelligence Analysis. <i>ACS Nano</i> , 2021, 15, 4054-4065.	7.3	53
539	Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). <i>Urology</i> , 2021, 149, 110-116.	0.5	4
540	The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations. <i>Journal of the National Cancer Institute</i> , 2021, 113, 626-631.	3.0	8
541	A Novel Curriculum on Using Life Expectancy to Inform Cancer Screening in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 524-529.	1.3	4

#	ARTICLE	IF	CITATIONS
542	N-acetylcysteine maintains penile length and erectile function in bilateral cavernous nerve crush rat model by reducing penile fibrosis. <i>Asian Journal of Andrology</i> , 2021, 23, 215.	0.8	3
543	Modulation of T-cell Regulators Associated with Advanced Stage of Prostate Cancer. <i>Acta Informatica Medica</i> , 2021, 29, 182.	0.5	0
544	Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program. , 2021, 17, 78-83.		1
545	Molecularly-Imprinted Nanomaterial-Based Surface Plasmon Resonance Biosensors in Molecular Diagnosis. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2021, , 1-28.	0.2	1
546	Criteria for Evaluating Multi-cancer Early Detection Tests. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 3.	0.1	9
547	Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review. <i>Investigative and Clinical Urology</i> , 2021, 62, 256.	1.0	7
548	Dealing with cancer screening in the COVID-19 era. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 86-90.	0.3	13
549	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
550	Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. <i>Clinical Chemistry</i> , 2021, 67, 602-609.	1.5	29
551	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2227.	1.8	2
552	Platelets as messengers of early-stage cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 563-573.	2.7	23
553	Clinical diagnosis of prostate cancer using digital rectal examination and prostate-specific antigen tests: a systematic review and meta-analysis of sensitivity and specificity. <i>African Journal of Urology</i> , 2021, 27, .	0.1	4
554	Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 209-249.	157.7	52,977
555	Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. <i>Metabolites</i> , 2021, 11, 181.	1.3	36
556	Prostate Cancer Screening and Young Black Men: Can Early Communication Avoid Later Health Disparities?. <i>Journal of Cancer Education</i> , 2022, 37, 1460-1465.	0.6	6
558	Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 845-851.	2.0	11
559	Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. <i>Oncologist</i> , 2021, 26, 537-548.	1.9	8
560	Evaluation of cell-free DNA accuracy as diagnostic biomarker for prostate cancer: A systematic review and meta-analysis. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 749-766.	1.4	0

#	ARTICLE	IF	CITATIONS
561	Long Noncoding RNA NEAT1 as a Potential Candidate Biomarker for Prostate Cancer. <i>Life</i> , 2021, 11, 320.	1.1	7
563	Is pre-biopsy serum prostate specific antigen retesting always justified? A study of the influence of individual and analytical factors on decision making for biopsy referral. <i>Clinica Chimica Acta</i> , 2021, 516, 77-82.	0.5	3
564	Effects of interstitial fluid pressure on shear wave elastography of solid tumors. <i>Extreme Mechanics Letters</i> , 2021, 47, 101366.	2.0	5
565	Reactions to Recommendations and Evidence About Prostate Cancer Screening Among White and Black Male Veterans. <i>American Journal of Men's Health</i> , 2021, 15, 155798832110221.	0.7	2
566	Decision fatigue in low-value prostate cancer screening. <i>Cancer</i> , 2021, 127, 3343-3353.	2.0	3
567	Interleukin-13 rs1800925/-1112C/T promoter single nucleotide polymorphism variant linked to anti-schistosomiasis in adult males in Murehwa District, Zimbabwe. <i>PLoS ONE</i> , 2021, 16, e0252220.	1.1	4
568	Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003616.	3.9	4
570	Navigating the Cancer Screening Decision for Patients with Dementia. <i>Current Oncology Reports</i> , 2021, 23, 90.	1.8	5
571	Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. <i>Cancers</i> , 2021, 13, 3381.	1.7	25
572	The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1869-1877.	1.4	2
573	Case of linear immunoglobulin A bullous dermatosis in a patient with prostate cancer. <i>Journal of Dermatology</i> , 2021, 48, e560-e561.	0.6	0
574	Urban-Rural Differences in Clinical Characteristics of Prostate Cancer at Initial Diagnosis: A Single-Center Observational Study in Anhui Province, China. <i>Frontiers in Oncology</i> , 2021, 11, 704645.	1.3	1
575	Evaluating the sustainability of a cancer screening intervention through a PRISM: The PreView experience. <i>Preventive Medicine Reports</i> , 2021, 23, 101443.	0.8	0
577	Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review. <i>JMIR Cancer</i> , 2021, 7, e30430.	0.9	6
578	Discontinuing Cancer Screening for Older Adults: a Comparison of Clinician Decision-Making for Breast, Colorectal, and Prostate Cancer Screenings. <i>Journal of General Internal Medicine</i> , 2022, 37, 1122-1128.	1.3	8
579	Barriers and Facilitators to Informed Decision-Making About Prostate Cancer Screening Among Black Men. <i>Journal of the American Board of Family Medicine</i> , 2021, 34, 925-936.	0.8	8
580	Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. <i>Annals of Oncology</i> , 2021, 32, 1167-1177.	0.6	363
581	Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722199718.	0.9	14



#	ARTICLE	IF	CITATIONS
582	Computer Aided Detection of Prostate Cancer Using T2, DWI and DCE MRI: Methods and Clinical Applications. Lecture Notes in Computer Science, 2010, , 4-14.	1.0	1
583	Serum long non-coding RNA LOC553103 as non-specific diagnostic and prognostic biomarker for common types of human cancer. Clinica Chimica Acta, 2020, 508, 69-76.	0.5	2
584	What we have learned from randomized trials of prostate cancer screening. Asian Journal of Andrology, 2011, 13, 369-373.	0.8	5
585	Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer. Asian Journal of Andrology, 2013, 15, 218-220.	0.8	3
586	Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. Journal of Cancer Education, 1998, 13, 213-9.	0.6	74
590	Reproducibility, Performance, and Clinical Utility of a Genetic Risk Prediction Model for Prostate Cancer in Japanese. PLoS ONE, 2012, 7, e46454.	1.1	30
591	The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening. PLoS ONE, 2016, 11, e0152999.	1.1	15
592	Association between features of patient-provider discussions and routine prostate-specific antigen testing. PLoS ONE, 2017, 12, e0177687.	1.1	8
593	Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth. PLoS ONE, 2017, 12, e0185995.	1.1	22
594	Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening. PLoS ONE, 2017, 12, e0190357.	1.1	14
595	Atti del 52° Congresso Nazionale: Societ� Italiana di Igiene, Medicina Preventiva e Sanit� Pubblica (SIItI). Journal of Preventive Medicine and Hygiene, 2019, 60, E1-E384.	0.9	4
596	Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 244-252.	0.7	7
597	Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 691-704.	0.7	9
598	Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 223-230.	0.7	13
599	Prostatic carcinoma bilateral iris metastases. Bosnian Journal of Basic Medical Sciences, 2017, 12, 134.	0.6	9
600	Primary epidemiological evaluation of the effectiveness of the All-National Dispensarization as a cancer screening by the data of the Arkhangelsk Regional Cancer Registry. Issledovani� I Praktika V Medicine, 2019, 6, 187-199.	0.1	5
601	Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates Epidermal Growth Factor Receptor in prostate cancer. Oncotarget, 2016, 7, 70388-70403.	0.8	15
602	Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. Oncotarget, 2017, 8, 69709-69721.	0.8	30

#	ARTICLE	IF	CITATIONS
603	Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia. <i>Oncotarget</i> , 2017, 8, 76987-76999.	0.8	14
604	Augmented Reality System for Digital Rectal Examination Training and Assessment: System Validation. <i>Journal of Medical Internet Research</i> , 2020, 22, e18637.	2.1	31
605	Web-Based Versus Usual Care and Other Formats of Decision Aids to Support Prostate Cancer Screening Decisions: Systematic Review and Meta-Analysis. <i>Journal of Medical Internet Research</i> , 2018, 20, e228.	2.1	38
606	Activation of the intrinsic-apoptotic pathway in LNCaP prostate cancer cells by genistein- topotecan combination treatments. <i>Functional Foods in Health and Disease</i> , 2013, 3, 66.	0.3	2
607	The Use of Biomarkers in Prostate Cancer Screening and Treatment. <i>Reviews in Urology</i> , 2017, 19, 221-234.	0.9	51
608	Dynamics and implications of models for intermittent androgen suppression therapy. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 187-204.	1.0	12
609	Prostate cancer for the internist. <i>North American Journal of Medical Sciences</i> , 2015, 7, 429.	1.7	14
610	Detection and Diagnostic Overall Accuracy Measures of Medical Tests. <i>Rambam Maimonides Medical Journal</i> , 2018, 9, e0027.	0.4	6
611	Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 43-52.	0.9	12
612	Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. <i>Canadian Urological Association Journal</i> , 2012, 6, 367-373.	0.3	36
613	Impact of PSA and DRE on Histologic Findings at Prostate Biopsy in Turkish Men Over 75 Years of Age. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6085-6088.	0.5	10
614	Uptake of prostate cancer screening and associated factors among Chinese men aged 50 or more: a population-based survey. <i>Cancer Biology and Medicine</i> , 2014, 11, 56-63.	1.4	17
615	Prostate Cancer: Locoregional Disease. <i>UNIPA Springer Series</i> , 2021, , 791-803.	0.1	0
616	Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1028-1033.	1.0	10
617	3D, large-area NiCo2O4 microflowers as a highly stable substrate for rapid and trace level detection of flutamide in biofluids via surface-enhanced Raman scattering (SERS). <i>Mikrochimica Acta</i> , 2021, 188, 371.	2.5	9
618	A Distributed Clinical Decision Support System Applied to Prostate Cancer Diagnosis. <i>Advances in Intelligent and Soft Computing</i> , 2010, , 365-372.	0.2	0
619	Implementation and Benefits of Computerized Physician Order Entry and Evidence-Based Clinical Decision Support Systems. , 2011, , 323-335.		1
621	Prostate Boundary Detection from Ultrasound Images using Ant Colony Optimization. <i>International Journal of Research in Computer Science</i> , 2011, 1, 39-48.	0.3	1

#	ARTICLE	IF	CITATIONS
622	Tumor Markers. , 2012, , 617-667.		1
623	Prostate Cancer Screening: A Review of the Evidence with Clinical Practice Implications. , 2012, , 25-49.		0
624	Future Directions in Prostate Cancer Diagnosis. , 2013, , 363-372.		0
625	Management of Concomitant Risk. , 2013, , 141-154.		0
626	Personalized Medicine: New Perspectives in Cancer Treatments. Metabolomics: Open Access, 2013, 03, .	0.1	0
627	Screening for Prostate Cancer: The Debate Continues. Journal of the Advanced Practitioner in Oncology, 2013, 4, 16-21.	0.2	1
628	Prevention of Prostate Cancer. , 2014, , 491-531.		0
629	Beyond the Standard of Care: The Role of Cytopathology in Molecular Testing of Cancer. Cancer Treatment and Research, 2014, 160, 273-282.	0.2	0
630	Rastreio do cancro prostÁtico: o actual paradigma da medicina centrada na pessoa. Revista Portuguesa De ClÁnica Geral, 2014, 30, 122-128.	0.1	1
631	Relationship between BMI, PSA and Histopathological Tumor Grade in a Caucasian Population Affected by Prostate Cancer. Global Journal of Medical and Clinical Case Reports, 0, , 014-019.	0.0	0
632	Epidemiology, Screening, Pathology and Pathogenesis. , 2015, , 677-695.		0
633	Prostate Cancer Diagnostic and Evaluation in Gaza-Strip, Palestine. Health, 2015, 07, 1552-1559.	0.1	0
634	The Ethical Dilemma Surrounding Prostate Specific Antigen (PSA) Screening. Journal of Clinical Research & Bioethics, 2015, 06, .	0.2	1
635	Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer. Advances in Modern Oncology Research, 2015, 1, .	0.1	0
636	Legal Implications of Prostate Cancer Screening. , 2016, , 613-619.		0
637	Impact of Comorbidity on Cancer Screening and Diagnosis. , 2016, , 105-129.		0
638	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2016, , 1-41.		0
640	The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients. Medwave, 2016, 16, e6501-e6501.	0.2	1

#	ARTICLE	IF	CITATIONS
641	Utilizing Biopsy-Based Genomic Assays to Risk-Stratify Patients. <i>Current Clinical Urology</i> , 2017, , 115-128.	0.0	0
643	RASTREIO DO CÂNCER DE PRÓSTATA: REVISÃO SISTEMÁTICA DA LITERATURA SOBRE AS PERSPECTIVAS MUNDIAIS. <i>Revista De Atenção À Saúde</i> , 2018, 16, .	0.0	0
644	Comorbidity in Aging and Cancer. , 2018, , 1-29.		0
645	Development and validation of a polygenic hazard score for aggressive prostate cancer identification. <i>Translational Cancer Research</i> , 2019, 8, S124-S125.	0.4	0
647	Relationship between Socioeconomic Status and Prevalent Prostate Cancer in the South Korea. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3137-3144.	0.5	8
648	Recommendations of Test of Prostate-specific Antigen along with Histopathological Examination for the Prostate Lesions. <i>Journal of Medical Sciences and Health</i> , 2019, 05, 28-32.	0.1	0
649	A Jaw-Dropping Diagnosis. <i>Journal of Hospital Medicine</i> , 2020, 15, 687-691.	0.7	0
651	Prostate Cancer Aggressiveness Prediction Using CT Images. <i>Life</i> , 2021, 11, 1164.	1.1	5
652	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. <i>Investigative and Clinical Urology</i> , 2020, 61, 411.	1.0	7
653	Does shared decision making increase prostate screening uptake in countries with a low prevalence of prostate cancer?. <i>African Health Sciences</i> , 2020, 20, 1870-4.	0.3	1
654	Comorbidity in Aging and Cancer. , 2020, , 365-393.		0
657	Increasing the value of PSA through improved implementation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, , .	0.8	0
658	Resultados de la rama española del Estudio Randomizado Europeo de Screening del Cáncer de Próstata (ERSPC). Actualización tras 21 años de seguimiento. <i>Actas Urológicas Españolas</i> , 2020, 44, 430-436.	0.3	1
660	Family and friend interactions among African-American men deciding whether or not to have a prostate cancer screening. <i>Urologic Nursing</i> , 2010, 30, 189-93, 166.	0.1	16
661	Serum protein electrophoresis in the evaluation of lytic bone lesions. <i>Iowa orthopaedic journal</i> , The, 2013, 33, 114-8.	0.5	1
662	Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 1854-60.	0.5	8
663	The relevance of the procedures related to the physiotherapy in the interventions in patients with prostate cancer: short review with practice approach. <i>International Journal of Biomedical Science</i> , 2014, 10, 73-84.	0.5	3
664	Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. <i>Indian Journal of Medical Research</i> , 2014, 139, 851-6.	0.4	10

#	ARTICLE	IF	CITATIONS
665	Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision. <i>Reviews in Urology</i> , 2015, 17, 171-7.	0.9	22
666	Oncoxin-Viucid may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. <i>Molecular and Clinical Oncology</i> , 2021, 14, 5.	0.4	2
667	Prostate cancer screening behaviors among Indo-Guyanese. <i>Cancer Causes and Control</i> , 2021, , 1.	0.8	1
668	miR-19a and miR-421 target PCA3 long non-coding RNA and restore PRUNE2 tumor suppressor activity in prostate cancer. <i>Molecular Biology Reports</i> , 2022, 49, 6803-6815.	1.0	7
669	Oncoxin-Viucid <sup>&amp;reg;</sup> may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. <i>Molecular and Clinical Oncology</i> , 2020, 14, 1-1.	0.4	3
670	Population-Based Penetrance of Deleterious Clinical Variants. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 350.	3.8	34
671	Examination of prostate-specific antigen (PSA) screening in military and civilian men: analysis of the 2018 behavioral risk factor surveillance system. <i>Cancer Causes and Control</i> , 2022, 33, 393-402.	0.8	4
673	Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review. <i>Value in Health Regional Issues</i> , 2022, 30, 31-38.	0.5	3
674	Opportunities for Early Cancer Detection: The Rise of ctDNA Methylation-Based Pan-Cancer Screening Technologies. <i>Epigenomes</i> , 2022, 6, 6.	0.8	14
675	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. <i>Cancers</i> , 2022, 14, 1004.	1.7	3
676	Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. <i>Frontiers in Public Health</i> , 2022, 10, 811044.	1.3	171
678	Comparison of US Cancer Center Recommendations for Prostate Cancer Screening With Evidence-Based Guidelines. <i>JAMA Internal Medicine</i> , 2022, , .	2.6	5
679	Raman Spectroscopy in Prostate Cancer: Techniques, Applications and Advancements. <i>Cancers</i> , 2022, 14, 1535.	1.7	18
681	On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13537.	1.8	11
682	Shared decision-making in urology and female pelvic floor medicine and reconstructive surgery. <i>Nature Reviews Urology</i> , 2022, 19, 161-170.	1.9	2
684	Monosaccharide-mediated rational synthesis of a universal plasmonic platform with broad spectral fluorescence enhancement for high-sensitivity cancer biomarker analysis. <i>Journal of Nanobiotechnology</i> , 2022, 20, 184.	4.2	2
685	Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1139-1145.	1.1	7
690	Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis. <i>Investigative and Clinical Urology</i> , 2022, 63, 251.	1.0	1

#	ARTICLE	IF	CITATIONS
693	The Evaluation of Goal-Directed Antibiotics Prophylaxis Applied Via Rectal Swab Before Transrectal Ultrasound-Guided Prostate Biopsy. <i>Åæroonkoloji BÅ¼lteni</i> , 2022, 21, 52-57.	0.1	1
694	How Much Information Do Icelandic Men Receive on Pros and Cons of Prostate-Specific Antigen Testing Prior to Undergoing Testing?. <i>American Journal of Men's Health</i> , 2022, 16, 155798832210978.	0.7	1
695	The knowledge and attitude towards prostate cancer and screening practices among males in Saudi Arabia. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2637.	0.3	2
696	Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study. <i>Cancers</i> , 2022, 14, 3135.	1.7	3
697	Screening and Prevention. , 2022, , 33-43.		0
698	The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	0.9	1
699	Metastatic Prostate Adenocarcinoma Presenting as Acute Quadriplegia: A Case Report and Racial Disparity Analysis. <i>Cureus</i> , 2022, , .	0.2	0
700	Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. <i>Nature Reviews Urology</i> , 2022, 19, 562-572.	1.9	55
701	Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years. <i>Clinical Cancer Research</i> , 2022, 28, 4926-4933.	3.2	2
702	Study of plasma proteome pattern using matrix-assisted laser-desorption ionization time of flight mass spectrometry in a cohort of Egyptian prostate cancer patients. <i>The Egyptian Journal of Laboratory Medicine</i> , 2020, 32, 84.	0.0	0
703	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
704	Synthetic Small Molecules in Prostate Cancer Therapeutics. , 2022, , 985-1004.		0
705	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
706	Combined MRI and PSA Strategy Improves Biopsy Decisions Compared with PSA Only: Longitudinal Observations of a Cohort of Patients with a PSA Level Less Than 20 ng/mL. <i>Academic Radiology</i> , 2022, , .	1.3	0
707	Evaluation of Harms Reporting in U.S. Cancer Screening Guidelines. <i>Annals of Internal Medicine</i> , 2022, 175, 1582-1590.	2.0	10
708	Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial. <i>Pharmacoeconomics</i> , 2022, 40, 1207-1220.	1.7	3
709	Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update. <i>Systematic Reviews</i> , 2022, 11, .	2.5	5
710	Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. <i>Journal of the National Cancer Institute</i> , 2023, 115, 190-199.	3.0	11

#	ARTICLE	IF	CITATIONS
711	The use of PSA testing over more than 20 years: A population-based study in North-Eastern Italy. <i>Tumori</i> , 2023, 109, 406-412.	0.6	1
712	Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. <i>Cancers</i> , 2022, 14, 4818.	1.7	42
714	Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 142-153.	1.4	6
715	A Pilot Study of <sup>68</sup> Ga-PSMA11 and <sup>68</sup> Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy. <i>Journal of Nuclear Medicine</i> , 2023, 64, 592-597.	2.8	5
716	A Pilot Study of <sup>68</sup> Ga-PSMA11 and <sup>68</sup> Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2023, 64, 744-750.	2.8	6
717	Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer. <i>Cancers</i> , 2022, 14, 5823.	1.7	4
718	Development of a Prediction Model for Positive Surgical Margin in Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Current Oncology</i> , 2022, 29, 9560-9571.	0.9	3
719	The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test. <i>Journal of Cancer Education</i> , 0, , .	0.6	1
720	Variables Associated with False-Positive PSA Results: A Cohort Study with Real-World Data. <i>Cancers</i> , 2023, 15, 261.	1.7	9
721	Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. <i>Cancer Medicine</i> , 2023, 12, 9116-9127.	1.3	5
723	Global Trends of Prostate Cancer by Age, and Their Associations With Gross Domestic Product (GDP), Human Development Index (HDI), Smoking, and Alcohol Drinking. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e261-e270.e50.	0.9	6
724	IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study. <i>Urology</i> , 2023, , .	0.5	0
725	Interactions of SNPs in Folate Metabolism Related Genes on Prostate Cancer Aggressiveness in European Americans and African Americans. <i>Cancers</i> , 2023, 15, 1699.	1.7	0
726	Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
727	Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion. <i>Diagnostics</i> , 2023, 13, 1373.	1.3	0
728	Human Prostate-Specific Antigen Carries N-Glycans with Ketodeoxynononic Acid. <i>Engineering</i> , 2023, 26, 119-131.	3.2	1
729	PSA density does not improve predictive accuracy of the UCSF CAPRA score. <i>Prostate</i> , 0, , .	1.2	0
741	Role of phospholipase A2 in prostate cancer. , 2023, , 39-54.		0

#	ARTICLE	IF	CITATIONS
742	Best Practices and Strategies for Medical Educators to Acknowledge and Address REHD in Educational Materials. IAMSE Manuals, 2023, , 69-117.	0.1	0